Facebook Twitter Youtube Vk Rss
Facebook Twitter Youtube Vk Rss
  Trending
Dermata Therapeutics Volume Alert March 24, 2023
DiamondHead Holdings hits New 52-week High Following Yesterday’s PIPE Investment News March 23, 2023
ZyVersa Therapeutics Higher in Premarket Trading March 23, 2023
T2 Biosystems Plans to Add Candida Auris Detection to T2Candida Panel March 23, 2023
SQZ Biotechnologies Confirms Complete Response in Clinical Trial March 23, 2023
Next
Prev

Lantern Pharma, Inc (NASDAQ: LTRN) Shares are Pushing Upward on News of FDA Authorization to Initiate Phase 2 of their Clinical Trial. The Stock is up over 18% at the Time of this Post.

  • Jul 14, 2022 at 6:23 AM

Lantern Pharma Receives FDA Authorization to Initiate its Phase 2 Clinical Trial, Harmonic, for LP-300 in Never Smokers with Non-Small Cell Lung Cancer

https://www.businesswire.com/news/home/20220714005308/en/Lantern-Pharma-Receives-FDA-Authorization-to-Initiate-its-Phase-2-Clinical-Trial-Harmonic%E2%84%A2-for-LP-300-in-Never-Smokers-with-Non-Small-Cell-Lung-Cancer

RelatedNews

Want more news like this? Check out our homepage!

Signup today for free and be the first to get notified of breaking news.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Recent News

Follow Us

Facebook-f Twitter Youtube

SIGN UP FOR OUR NEWSLETTER

Sign up for Breaking Alerts, our newsletter putting timely and updated stock and crypto markets news into your hands.

24/7 MarketNews is a leading market news platform for public companies. As a pioneer in digital media, we are dedicated to the swift distribution of financial market news and information. We take great pride in creating innovative public relations campaigns that help our clients reach their target audience.

Search by keyword

© 2022-2023 24/7MarketNews – The Experts in Investor and Public Relations

Add New Playlist

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.